Rezultati - Petr Zatloukal

  • Showing 1 - 12 results of 12
Refine Results
  1. 1
    Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL)

    Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL) od Natasha B. Leighl, Petr Zatloukal, J. Mezger, Rodryg Ramlau, N. Moore, Martin Reck, Christian Manegold

    Izdano 2010
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    A3-03: Pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC): Results from a randomized phase III dose finding trial in patients who progressed following platinum-containing chemotherapy

    A3-03: Pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC): Results from a randomized phase III dose finding trial in patients who progressed following plat... od Michael Cullen, Petr Zatloukal, Sverre Sörenson, Silvia Novello, Juergen R. Fischer, Joy Abraham, Manuela Zereu, Patrick Peterson, Carla Visseren‐Grul, Neill Iscoe

    Izdano 2007
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease

    A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with... od Petr Zatloukal, F. Cardenal, A. Szczęsna, В. А. Горбунова, Vladimir Moiseyenko, Xiu Juan Zhang, Laura A. Cisar, Jean‐Charles Soria, Manuel Dómine, Michael Thomas

    Izdano 2010
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

    Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (... od Martin Reck, Joachim von Pawel, Petr Zatloukal, Rodryg Ramlau, V. Gorbounova, Vera Hirsh, N. B. Leighl, J. Mezger, Venice Archer, Norman C. Moore, C. Manegold

    Izdano 2010
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

    Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus... od E.H. Tan, Janusz Rolski, Tomasz Grodzki, C. Schneider, U. Gatzemeier, Petr Zatloukal, Enrico Aitini, Giacomo Cartenì, H Riska, Y H Tsai, Raymond P. Abratt

    Izdano 2009
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis

    Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis od Andrea Ardizzoni, Luca Boni, Marcello Tiseo, Frank V. Fossella, Joan H. Schiller, Marianne Paesmans, Davorin Radosavljević, Adriano Paccagnella, Petr Zatloukal, Paola Mazzanti, D. Bisset, R. Rosell

    Izdano 2007
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy

    Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy od Karen Kelly, Christopher G. Azzoli, Petr Zatloukal, István Albert, Peter Jiang, David Bodkin, José Rodrigues Pereira, Erzsébet Juhász, Nicholas Iannotti, Garry Weems, Tony Koutsoukos, Jyoti D. Patel

    Izdano 2012
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Phase III Study of Adjuvant Vaccination With Bec2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)

    Phase III Study of Adjuvant Vaccination With Bec2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and... od Giuseppe Giaccone, Channa Debruyne, Enriqueta Felip, Paul B. Chapman, Stefan C. Grant, Michael Millward, Luc Thiberville, Giannicola DʼAddario, Corneel Coens, Lisa Rome, Petr Zatloukal, Oriol Massó, Catherine Legrand

    Izdano 2005
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Randomized Phase III Trial Comparing Bexarotene (L1069-49)/Cisplatin/Vinorelbine With Cisplatin/Vinorelbine in Chemotherapy-Naïve Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: SPIRIT I

    Randomized Phase III Trial Comparing Bexarotene (L1069-49)/Cisplatin/Vinorelbine With Cisplatin/Vinorelbine in Chemotherapy-Naïve Patients With Advanced or Metastatic Non–Small-Cel... od Rodryg Ramlau, Petr Zatloukal, Jacek Jassem, Paul Schwarzenberger, С. В. Орлов, Maya Gottfried, José Rodrigues Pereira, G Temperley, Rosa Negro‐Vilar, Samia Rahal, Joseph K. Zhang, A. Negro‐Vilar, Zofia E. Dziewanowska

    Izdano 2008
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  10. 10
    A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

    A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer od C. Manegold, Nico van Zandwijk, A. Szczęsna, Petr Zatloukal, Joseph S. K. Au, Maria Błasińska-Morawiec, Piotr Serwatowski, Maciej Krzakowski, Jacek Jassem, E.H. Tan, Rebecca Benner, Antonella Ingrosso, Sandra J. Meech, David Readett, N. Thatcher

    Izdano 2011
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  11. 11
    Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer

    Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer od Jean‐Charles Soria, Z. Mark, Petr Zatloukal, B. Szima, István Albert, Erzsébet Juhász, Jean-Louis Pujol, Jerzy Kozielski, Nigel Baker, Dominic Smethurst, Yong‐jiang Hei, Avi Ashkenazi, Howard M. Stern, Lukas C. Amler, Yang Pan, Fiona Blackhall

    Izdano 2011
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  12. 12
    Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

    Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) od Suresh S. Ramalingam, Jeffrey Crawford, Alex Y. Chang, C. Manegold, Román Pérez-Soler, Jean-Yves Douillard, Nicholas Thatcher, Fabrice Barlési, Taofeek K. Owonikoko, Y. Wang, Philippe Pultar, Jing Zhu, Rajesh Malik, Giuseppe Giaccone, Stephen Della‐Fiorentina, Stephen Begbie, Ross Jennens, Joshua Dass, K. Pittman, N.M. Ivanova, Tatyana Koynova, Petar Petrov, Antoaneta Tomova, Valentina Tzekova, Félix Couture, Vera Hirsh, Ronald L. Burkes, Randeep Sangha, Miloslav Ambruš, Terezie Janaskova, J Musil, J. Novotny, Petr Zatloukal, Jitka Jakesova, Kamil Klenha, Jaromı́r Roubec, J Vaňásek, Jérôme Fayette, Fabrice Barlési, Jaafar Bennouna-Louridi, C. Chouaïd, Julien Mazières, H. Vallerand, G. Robinet, P.-J. Souquet, D. Spaëth, Roland Schött, H. Léna, Y. Martinet, Claude El Kouri, Nathalie Baize, Arnaud Scherpereel, O. Molinier, F. Fuchs, K. Josten, C. Manegold, Norbert Marschner, Folker Schneller, Tobias R. Overbeck, Michael Thomas, Joachim von Pawel, Martin Reck, Wolfgang Schuette, Volker Hagen, Claus-Peter Schneider, V. Georgoulias, Ioannis Varthalitis, Kostas Zarogoulidis, K. Syrigos, Christos N. Papandreou, Csaba Böcskei, Eszter Csánky, Erzsébet Juhász, György Losonczy, Z. Mark, István Molnár, Zsolt Pápai-Székely, S. Tehenes, Ilona Vinkler, Sachin Almel, Ashish Bakshi, Shailesh Bondarde, A Maru, Ashutosh Pathak, R.M. Pedapenki, Krishna Prasad, S.V.S.S. Prasad, Nalini Kilara, D. Gorijavolu, Chetan Deshmukh, S.K.P. John, Lalit Mohan Sharma, D. Amoroso, Emilio Bajetta, Paolo Bidoli, Andrea Bonetti, Filippo de Marinis, Massimo Di Maïo, Rodolfo Passalacqua, Stefano Cascinu

    Izdano 2013
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: